A swallowable microparticle vaccine carrying a peptide from a tumor-associated protein significantly slowed ovarian cancer progression in mice by activating cancer-killing immune cells.
p = 0.005Vaccinated mice showed significantly less tumor growth than placebo-treated animals four weeks after being challenged with ovarian cancer cells
What the researchers found
Mice that received the oral microparticle vaccine showed strong activation of IFN-γ+/CD8+ T cells (cancer-killing immune cells) when re-exposed to the SP17 antigen. Vaccinated animals had significantly less ascites and tumor volume compared to placebo-treated animals four weeks after tumor challenge (p = 0.005).
The microparticles were engineered with enteric coatings to survive the stomach, sustained-release polymers for prolonged antigen exposure, and Aleuria aurantia lectin to specifically target M cells in the gut's immune tissue — making this a sophisticated oral delivery platform for peptide-based cancer immunotherapy.
Why it matters
Ovarian cancer is the fifth leading cause of cancer death in women and often recurs after initial treatment. An oral vaccine that can be swallowed rather than injected could make cancer immunotherapy more accessible and practical as a maintenance treatment. This study demonstrates that peptide antigens can be effectively delivered through the gut to generate meaningful anti-tumor immune responses.
How the study worked
Researchers created spray-dried microparticles containing an immunodominant peptide epitope from sperm protein 17 (SP17) along with a CpG oligonucleotide immune stimulant. The particles were coated with gut-targeting lectin and acid-resistant polymers. Mice were first challenged with SP17-expressing ovarian cancer cells (ID8 line), then given the oral vaccine one week later. Immune responses were measured by analyzing spleen cells for activated CD8+ T cells, and tumor burden was assessed by measuring ascites and tumor volume at four weeks.
What this study cannot tell us
This was a mouse study using a xenograft tumor model, which does not fully replicate human ovarian cancer biology. The sample size details for the animal groups were not specified in the abstract. The long-term durability of the immune response and whether it could prevent recurrence over months or years was not assessed. Translation to humans faces significant hurdles including differences in gut immune system architecture.
How to read the evidence
This is a preclinical animal study using a mouse tumor model. While the results are statistically significant and mechanistically promising, the findings have not been tested in human clinical trials and represent early-stage evidence.
When this study was published
Published in 2019, this study represents ongoing work in oral peptide vaccine delivery for cancer. The BSK02 platform's development status and any subsequent clinical translation would need to be verified.
The bigger picture
Most cancer vaccines require injection, which limits their use as long-term maintenance therapies. This study is part of a broader effort to develop oral cancer vaccines using peptide-loaded microparticles that can target the gut immune system. If successful in humans, this approach could transform how cancer patients receive follow-up immunotherapy — potentially as a pill taken at home rather than an injection given in a clinic.
Questions still open
- Would this oral vaccine platform generate strong enough immune responses in humans to meaningfully slow ovarian cancer recurrence?
- Could this microparticle delivery system be adapted to carry peptides targeting other types of cancer?
- How long does the immune memory from this oral vaccination last, and would booster doses be needed?
Common questions
How does an oral vaccine reach the immune system without being destroyed by stomach acid?
What is sperm protein 17 and why target it for ovarian cancer?
Read the original research
Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17.
Journal of biomedical materials research. Part B, Applied biomaterials, 107(1), 29-36
Citation
Mattila, Juha-Pekka; Mirandola, Leonardo; Chiriva-Internati, Maurizio. (2019). Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17.. Journal of biomedical materials research. Part B, Applied biomaterials, 107(1), 29-36. https://doi.org/10.1002/jbm.b.34092